

Resource Summary Report

Generated by [RRID](#) on Aug 21, 2026

pTwist-SARS-CoV ?18

RRID:Addgene_169465

Type: Plasmid

Proper Citation

RRID:Addgene_169465

Plasmid Information

URL: <http://www.addgene.org/169465>

Proper Citation: RRID:Addgene_169465

Insert Name: SARS-CoV Spike truncated to remove 18 amino acids

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:33743213](#)

Vector Backbone Description: Vector Backbone:pTwist; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: pTwist-SARS-CoV ?18

Record Creation Time: 20220422T221949+0000

Record Last Update: 20260815T081001+0000

Ratings and Alerts

No rating or validation information has been found for pTwist-SARS-CoV ?18.

No alerts have been found for pTwist-SARS-CoV ?18.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Roederer AL, et al. (2026) SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization. *Cell reports*, 45(2), 116954.

Jung I, et al. (2025) Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies. *Molecular pharmaceutics*, 22(9), 5316.

Patel SV, et al. (2025) Cross-Neutralization of Distant Coronaviruses Strongly Correlates with Spike S2-Specific Antibodies from Immunocompetent and Immunocompromised Vaccinated SARS-CoV-2-Infected Patients. *Vaccines*, 13(9).

Thimmiraju SR, et al. (2024) Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. *Viruses*, 16(9).

Thimmiraju SR, et al. (2024) A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. *NPJ vaccines*, 9(1), 132.

Patel SV, et al. (2024) Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients. *Research square*.